Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Methamphetamine Clear all
Completed Phase 1 Interventional

Oxytocin HIV Meth Study

NCT02881177
View directory record Official record
Conditions
Amphetamine Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 6, 2026, 12:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Open-Label Creatine Study for Female Meth Users

NCT02189915
View directory record Official record
Conditions
Depression, Dual Diagnosis, Substance Use
Interventions
Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
13 Years to 55 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 6, 2026, 12:50 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07693608
View directory record Official record
Conditions
Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
Interventions
Tirzepatide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

NCT00318409
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Bupropion, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 6, 2026, 12:50 PM EDT
Recruiting Not applicable Interventional

Deep TMS of Neural Circuits Associated With Stimulant Use Disorder

NCT06578429
View directory record Official record
Conditions
Methamphetamine Use Disorder, Transcranial Magnetic Stimulation
Interventions
Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active, Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham
Device
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 6, 2026, 12:50 PM EDT
Terminated Phase 2 Interventional Results available

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

NCT04715230
View directory record Official record
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
IXT-m200, Lorazepam, Haloperidol
Biological · Drug
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Everett, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 6, 2026, 12:50 PM EDT
Not listed Not applicable Interventional

Floatation-REST in Methamphetamine Use Disorder: A Pilot Study

NCT05799209
View directory record Official record
Conditions
Amphetamine-Type Substance Use Disorder
Interventions
Float Pool, Float Chair
Device
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Not applicable Interventional Results available

Pilot TMS for Methamphetamine Use Disorder

NCT04449055
View directory record Official record
Conditions
Stimulant Dependence, Methamphetamine-dependence, Addiction, Drug
Interventions
Transcranial Magnetic Stimulation--DPFC first, MPFC second, Transcranial Magnetic Stimulation--MPFC first, DPFC second
Device
Lead sponsor
Ryan M. Carnahan
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin for Methamphetamine Use Disorder

NCT07774702
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Drug · Behavioral
Lead sponsor
Peter Hendricks
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 1Phase 2 Interventional

Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder

NCT03382379
View directory record Official record
Conditions
Amphetamine Use Disorders
Interventions
Active transcranial Direct Current Stimulation (tDCS), Sham transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 1 Interventional

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Placebo, Rivastigmine
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 2 Interventional

Bupropion for the Treatment of Methamphetamine Dependence - 1

NCT00069251
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Costa Mesa, California • San Diego, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

NCT00497081
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
mirtazapine, placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Not applicable Interventional Results available

Long-term Behavior Change - 1

NCT00158197
View directory record Official record
Conditions
Amphetamine-related Disorders
Interventions
contingency management voucher
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Not applicable Interventional

Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)

NCT01122186
View directory record Official record
Conditions
HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use, HIV Infections
Interventions
Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 6, 2026, 12:50 PM EDT
Recruiting Not applicable Interventional

PrEP Readiness Interventions for Sustained Motivation (PRISM)

NCT06637436
View directory record Official record
Conditions
HIV, Methamphetamine Disorders
Interventions
Motivational Interviewing (MI), Contingency Management (CM)
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Recruiting Not applicable Interventional

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

NCT06532370
View directory record Official record
Conditions
Contingency Managment, Methamphetamine Use Disorder
Interventions
Contingency Managment
Behavioral
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Phase 2 Interventional

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

NCT00284206
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 6, 2026, 12:50 PM EDT
Recruiting Not applicable Interventional

Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use

NCT07365293
View directory record Official record
Conditions
Substance Related Disorders
Interventions
Just Care for Families (JCFF), Just Care for Families (JCFF) App, Just Care for Families (JCFF) App Feedback
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Not listed Phase 1 Interventional

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Reserpine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 6, 2026, 12:50 PM EDT
Active, not recruiting Phase 2 Interventional

Tirzepatide for Obesity and Meth Use Disorder

NCT06745128
View directory record Official record
Conditions
Obesity, Methamphetamine Use Disorder
Interventions
Tirzepatide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 6, 2026, 12:50 PM EDT
Completed Not applicable Interventional

Mood and Decision-making in Methamphetamine Use Disorder

NCT06410196
View directory record Official record
Conditions
Methamphetamine Abuse
Interventions
Mood modulation
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 6, 2026, 12:50 PM EDT
Recruiting Early Phase 1 Interventional

Methamphetamine and Troriluzole

NCT06989853
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Placebo, Methamphetamine
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 6, 2026, 12:50 PM EDT